AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
5,241.00
-104.00 (-1.95%)
At close: 4:47PM BST
Stock chart is not supported by your current browser
Previous close5,345.00
Open5,201.00
Bid5,050.00 x 6100
Ask5,300.00 x 13000
Day's range5,165.00 - 5,266.00
52-week range4,260.00 - 5,520.00
Volume3,413,560
Avg. volume2,294,017
Market cap66.383B
Beta0.98
PE ratio (TTM)22.11
EPS (TTM)237.00
Earnings date26 Jul 2018
Forward dividend & yield2.02 (4.06%)
Ex-dividend date2018-02-15
1y target est76.66
  • AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?
    Investor's Business Daily2 days ago

    AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?

    AstraZeneca dipped early Friday after the U.K.-based pharmaceutical company lagged first-quarter expectations for sales and core earnings.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks2 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Astrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript
    Motley Fool2 days ago

    Astrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript

    AZN earnings call for the period ending March 31, 2018.

  • AstraZeneca pay report rejected by 35 percent of shareholders
    Reuters2 days ago

    AstraZeneca pay report rejected by 35 percent of shareholders

    More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.

  • AstraZeneca pay report rejected by 35 percent of shareholders
    Reuters2 days ago

    AstraZeneca pay report rejected by 35 percent of shareholders

    More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.

  • Reuters - UK Focus2 days ago

    AstraZeneca pay report rejected by 35 pct of shareholders

    More than a third of AstraZeneca (Swiss: AZN.SW - news) shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca (NYSE: AZN - news) engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.

  • MarketWatch2 days ago

    U.K. stocks fall from record as AstraZeneca, mining stocks decline

    FTSE 100 on track for longest weekly win run since 2005ReutersAstraZeneca shares are losing ground Friday. U.K. stocks ended lower on Friday, pulling back from the previous session’s record close, as shares of AstraZeneca declined following the heavyweight drugmaker’s earnings report, and as shares in mining companies skidded in the wake of a selloff in metals prices. The FTSE 100 index (^FTSE) dropped 0.1% to close at 7,778.79, breaking a three-day winning streak.

  • Commodities help FTSE seal eight-week winning streak
    Reuters2 days ago

    Commodities help FTSE seal eight-week winning streak

    Britain's leading stock index posted its eighth straight week of gains despite dipping slightly on Friday as investor enthusiasm waned following the previous day's record close. The FTSE 100 ended the session down 0.1 percent at 7,778.79 points, in line with the FTSE 250 which hit a fresh record earlier in the session before turning lower. The FTSE sealed its longest winning streak in 13 years, marking a strong comeback for British stocks.

  • Reuters - UK Focus2 days ago

    Commodities help FTSE seal eight-week winning streak

    Britain's leading stock index posted its eighth straight week of gains despite dipping slightly on Friday as investor enthusiasm waned following the previous day's record close. The FTSE 100 ended the ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-Closing snapshot: STOXX posts best weekly streak since 2014

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-France vs Germany: here's a reality-check for Macron believers

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-Italy: no surprises there

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-Strong dollar a boost for European equities

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
    Zacks2 days ago

    AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

    AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-Why European shares can relax about bond yields (and the U.S. can't)

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-It's buyback season, yay!

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-Earnings have been ... not so strong

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-Midday snapshot: stocks lose steam

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-How much Italian spending could markets handle?

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • MarketWatch2 days ago

    Italian stocks lead Europe lower as politics spook traders

    The Stoxx Europe 600 index (^STOXX) tipped about 0.1% lower to 395.44, on track to break a three-day winning run. Italy’s FTSE MIB Index (MTAA:FTSEMIB.MI) slumped 1% to 23,564.03, as political developments in the country flustered markets. In the U.K., the FTSE 100 index (^FTSE) slipped 0.2% to 7,774.39, but was still on track for a 0.6% weekly advance.

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-Greedy or fearful? Quite the contrary

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus2 days ago

    LIVE MARKETS-Italian government pact hits stocks

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • AstraZeneca insists future is bright after big Crestor sales hit
    Reuters2 days ago

    AstraZeneca insists future is bright after big Crestor sales hit

    AstraZeneca's (AZN.L) first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018. Core operating profit tumbled 46 percent to $896 million (663 million pounds), well below market forecasts, and Crestor sales fell 38 percent as cheap copycat versions of the drug stole market share in Europe and Japan. Chief Executive Pascal Soriot said on Friday the performance was in line with his expectations, adding that the company's latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - had both got off to a strong start.

  • Reuters - UK Focus2 days ago

    AstraZeneca insists future is bright after big Crestor sales hit

    AstraZeneca's first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018. Core operating profit tumbled 46 percent to $896 million, well below market forecasts, and Crestor sales fell 38 percent as cheap copycat versions of the drug stole market share in Europe and Japan. Chief Executive Pascal Soriot said on Friday the performance was in line with his expectations, adding that the company's latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - had both got off to a strong start.

  • Reuters - UK Focus2 days ago

    Commodities put FTSE on track for eight-week winning streak

    Britain's leading stock index was on track for its eighth straight week of gains despite dipping slightly on Friday as investor enthusiasm waned after the previous day's record close. The FTSE 100 was ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes